25 XP   0   0   10

Cyteir Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Cyteir together

PenkeI guess you are interested in Cyteir Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cyteir Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cyteir Therapeutics Inc

I send you an email if I find something interesting about Cyteir Therapeutics Inc.

Quick analysis of Cyteir (30 sec.)










What can you expect buying and holding a share of Cyteir? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.06
Expected worth in 1 year
$-0.49
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-4.56
Return On Investment
-150.9%

For what price can you sell your share?

Current Price per Share
$3.02
Expected price per share
$2.96 - $3.19
How sure are you?
50%

1. Valuation of Cyteir (5 min.)




Live pricePrice per Share (EOD)

$3.02

Intrinsic Value Per Share

$-15.39 - $-18.30

Total Value Per Share

$-11.32 - $-14.24

2. Growth of Cyteir (5 min.)




Is Cyteir growing?

Current yearPrevious yearGrowGrow %
How rich?$146.2m$187.2m-$41m-28.0%

How much money is Cyteir making?

Current yearPrevious yearGrowGrow %
Making money-$43.9m-$41.6m-$2.3m-5.2%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cyteir (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#310 / 1011

Most Revenue
#1002 / 1011

Most Profit
#872 / 1011

Most Efficient
#445 / 1011

What can you expect buying and holding a share of Cyteir? (5 min.)

Welcome investor! Cyteir's management wants to use your money to grow the business. In return you get a share of Cyteir.

What can you expect buying and holding a share of Cyteir?

First you should know what it really means to hold a share of Cyteir. And how you can make/lose money.

Speculation

The Price per Share of Cyteir is $3.02. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cyteir.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cyteir, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.06. Based on the TTM, the Book Value Change Per Share is $-1.14 per quarter. Based on the YOY, the Book Value Change Per Share is $6.54 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cyteir.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.28-42.4%-1.28-42.4%-1.17-38.7%-0.86-28.5%-0.86-28.5%
Usd Book Value Change Per Share-1.14-37.7%-1.14-37.7%6.54216.5%1.0233.6%1.0233.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.14-37.7%-1.14-37.7%6.54216.5%1.0233.6%1.0233.6%
Usd Price Per Share1.65-1.65-11.37-3.26-3.26-
Price to Earnings Ratio-1.29--1.29--9.72--2.75--2.75-
Price-to-Total Gains Ratio-1.45--1.45-1.74-0.15-0.15-
Price to Book Ratio0.41-0.41-2.19-0.65-0.65-
Price-to-Total Gains Ratio-1.45--1.45-1.74-0.15-0.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.02
Number of shares331
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.141.02
Usd Total Gains Per Share-1.141.02
Gains per Quarter (331 shares)-377.05336.27
Gains per Year (331 shares)-1,508.191,345.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1508-1518013451335
20-3016-3026026902680
30-4525-4534040354025
40-6033-6042053805370
50-7541-7550067256715
60-9049-9058080718060
70-10557-10566094169405
80-12066-1207401076110750
90-13574-1358201210612095
100-15082-1509001345113440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.04.00.00.0%0.04.00.00.0%0.04.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.03.00.025.0%1.03.00.025.0%1.03.00.025.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.04.00.0%0.00.04.00.0%0.00.04.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.03.00.025.0%1.03.00.025.0%1.03.00.025.0%

Fundamentals of Cyteir

About Cyteir Therapeutics Inc

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 05:43:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cyteir Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cyteir earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cyteir to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cyteir Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-47,012.5%+47,012.5%
5Y-47,012.5%10Y-47,012.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM--211.9%+211.9%
YOY--277.7%+277.7%
5Y-47,012.5%-432.9%-46,579.6%
10Y-47,012.5%-599.3%-46,413.2%
1.1.2. Return on Assets

Shows how efficient Cyteir is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cyteir to the Biotechnology industry mean.
  • -28.7% Return on Assets means that Cyteir generated $-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cyteir Therapeutics Inc:

  • The MRQ is -28.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -28.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.7%TTM-28.7%0.0%
TTM-28.7%YOY-21.3%-7.4%
TTM-28.7%5Y-62.4%+33.7%
5Y-62.4%10Y-62.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.7%-13.3%-15.4%
TTM-28.7%-12.7%-16.0%
YOY-21.3%-11.8%-9.5%
5Y-62.4%-14.0%-48.4%
10Y-62.4%-15.9%-46.5%
1.1.3. Return on Equity

Shows how efficient Cyteir is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cyteir to the Biotechnology industry mean.
  • -30.0% Return on Equity means Cyteir generated $-0.30 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cyteir Therapeutics Inc:

  • The MRQ is -30.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -30.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.0%TTM-30.0%0.0%
TTM-30.0%YOY-22.2%-7.8%
TTM-30.0%5Y-13.1%-17.0%
5Y-13.1%10Y-13.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.0%-16.9%-13.1%
TTM-30.0%-16.0%-14.0%
YOY-22.2%-15.1%-7.1%
5Y-13.1%-19.7%+6.6%
10Y-13.1%-20.5%+7.4%

1.2. Operating Efficiency of Cyteir Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cyteir is operating .

  • Measures how much profit Cyteir makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cyteir to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cyteir Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-50,328.1%+50,328.1%
5Y-50,328.1%10Y-50,328.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM--224.4%+224.4%
YOY--288.3%+288.3%
5Y-50,328.1%-479.5%-49,848.6%
10Y-50,328.1%-625.2%-49,702.9%
1.2.2. Operating Ratio

Measures how efficient Cyteir is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cyteir Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y503.678-503.678
5Y503.67810Y503.6780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM-3.266-3.266
YOY-3.783-3.783
5Y503.6785.657+498.021
10Y503.6787.783+495.895

1.3. Liquidity of Cyteir Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cyteir is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 28.07 means the company has $28.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cyteir Therapeutics Inc:

  • The MRQ is 28.073. The company is very able to pay all its short-term debts. +2
  • The TTM is 28.073. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ28.073TTM28.0730.000
TTM28.073YOY25.706+2.367
TTM28.0735Y18.270+9.803
5Y18.27010Y18.2700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.0733.905+24.168
TTM28.0734.212+23.861
YOY25.7065.337+20.369
5Y18.2706.062+12.208
10Y18.2706.401+11.869
1.3.2. Quick Ratio

Measures if Cyteir is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cyteir to the Biotechnology industry mean.
  • A Quick Ratio of 27.68 means the company can pay off $27.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cyteir Therapeutics Inc:

  • The MRQ is 27.680. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 27.680. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ27.680TTM27.6800.000
TTM27.680YOY25.264+2.416
TTM27.6805Y17.812+9.869
5Y17.81210Y17.8120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.6803.572+24.108
TTM27.6804.001+23.679
YOY25.2645.364+19.900
5Y17.8126.009+11.803
10Y17.8126.287+11.525

1.4. Solvency of Cyteir Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cyteir assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cyteir to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.05 means that Cyteir assets are financed with 4.5% credit (debt) and the remaining percentage (100% - 4.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cyteir Therapeutics Inc:

  • The MRQ is 0.045. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.045. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.045TTM0.0450.000
TTM0.045YOY0.041+0.004
TTM0.0455Y1.622-1.576
5Y1.62210Y1.6220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0450.336-0.291
TTM0.0450.334-0.289
YOY0.0410.271-0.230
5Y1.6220.366+1.256
10Y1.6220.389+1.233
1.4.2. Debt to Equity Ratio

Measures if Cyteir is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cyteir to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.7% means that company has $0.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cyteir Therapeutics Inc:

  • The MRQ is 0.047. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.047. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.047TTM0.0470.000
TTM0.047YOY0.043+0.004
TTM0.0475Y0.023+0.025
5Y0.02310Y0.0230.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0470.382-0.335
TTM0.0470.397-0.350
YOY0.0430.341-0.298
5Y0.0230.432-0.409
10Y0.0230.465-0.442

2. Market Valuation of Cyteir Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cyteir generates.

  • Above 15 is considered overpriced but always compare Cyteir to the Biotechnology industry mean.
  • A PE ratio of -1.29 means the investor is paying $-1.29 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cyteir Therapeutics Inc:

  • The EOD is -2.360. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.290. Based on the earnings, the company is expensive. -2
  • The TTM is -1.290. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.360MRQ-1.290-1.071
MRQ-1.290TTM-1.2900.000
TTM-1.290YOY-9.716+8.427
TTM-1.2905Y-2.751+1.462
5Y-2.75110Y-2.7510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.360-2.262-0.098
MRQ-1.290-2.599+1.309
TTM-1.290-2.674+1.384
YOY-9.716-4.133-5.583
5Y-2.751-6.258+3.507
10Y-2.751-6.171+3.420
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cyteir Therapeutics Inc:

  • The EOD is -2.537. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.386. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.386. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.537MRQ-1.386-1.151
MRQ-1.386TTM-1.3860.000
TTM-1.386YOY-10.996+9.610
TTM-1.3865Y-3.096+1.709
5Y-3.09610Y-3.0960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.537-2.913+0.376
MRQ-1.386-3.275+1.889
TTM-1.386-3.508+2.122
YOY-10.996-5.620-5.376
5Y-3.096-8.306+5.210
10Y-3.096-8.854+5.758
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cyteir is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.41 means the investor is paying $0.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cyteir Therapeutics Inc:

  • The EOD is 0.743. Based on the equity, the company is cheap. +2
  • The MRQ is 0.406. Based on the equity, the company is cheap. +2
  • The TTM is 0.406. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.743MRQ0.406+0.337
MRQ0.406TTM0.4060.000
TTM0.406YOY2.185-1.779
TTM0.4065Y0.648-0.242
5Y0.64810Y0.6480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7431.858-1.115
MRQ0.4062.090-1.684
TTM0.4062.091-1.685
YOY2.1852.866-0.681
5Y0.6483.488-2.840
10Y0.6483.836-3.188
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cyteir Therapeutics Inc.

3.1. Institutions holding Cyteir Therapeutics Inc

Institutions are holding 76.833% of the shares of Cyteir Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BML Capital Management LLC9.02837.4835325000800
2023-12-31Newtyn Management LLC8.39351.8031302150052105620.8385
2023-09-30OUP Management Co., LLC6.832515.709245957200
2023-12-31Gabelli Funds LLC3.08360.0261110050667412150.7805
2023-12-31Anson Funds Management LP3.04580.41211096422-227692-17.1958
2023-12-31Gabelli Securities Inc2.85020.58511026000609800146.5161
2023-12-31Vanguard Group Inc1.90950.0001687391466117.2741
2023-12-31Millennium Management LLC1.25560.00064519804519800
2023-12-31Walleye Trading Advisors, LLC1.18630.00284270377312120.6606
2023-09-30LAURION CAPITAL MANAGEMENT LP0.99870.006235950000
2023-12-31Bulldog Investors, LLC0.55560.199820000000
2023-12-31Geode Capital Management, LLC0.49430.0001177930143938.8011
2023-12-31Aldebaran Capital LLC0.39930.447414373900
2023-12-31RBF LLC0.32580.021611729500
2023-12-31BlackRock Inc0.254409157859947.0036
2023-12-31Bank of America Corp0.2481089304883010.9725
2023-12-31Northern Trust Corp0.18970682833409499.7221
2023-12-31Squarepoint Ops LLC0.18670.0004672191634132.118
2023-12-31Bank of Montreal0.18420.000166300663000
2023-12-31BMO Capital Markets Corp.0.18420.000166300663000
Total 41.606326.69814977408+2354540+15.7%

3.2. Funds holding Cyteir Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Total Stock Mkt Idx Inv1.51420.0001545089273865.2899
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.47140.000616968800
2023-12-31Fidelity Extended Market Index0.27080.000897483-245-0.2507
2024-02-28iShares Micro-Cap ETF0.18350.0227660694290.6536
2023-12-31Fidelity Series Total Market Index0.07450.00012683100
2023-12-31Fidelity Nasdaq Composite Index0.06120.00052203500
2023-12-31NT Ext Equity Mkt Idx Fd - L0.05440.0011959600
2023-12-31Northern Trust Extended Eq Market Idx0.05440.0011959600
2024-01-31Schwab Total Stock Market Index0.04440.00021597200
2023-12-31Fidelity Total Market Index0.0440.00011583000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0380.00071368500
2023-12-31Spartan Total Market Index Pool E0.03130.00011125900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.03050.000710991210.1914
2023-10-31Comstock Capital Value A0.02780.4918100006500185.7143
2024-01-31LUX IM Global Medtech HX0.01620.0086584000
2023-12-311290 VT Micro Cap K0.01350.0101486868016.2369
2023-12-31Spartan Extended Market Index Pool E0.01210.000643532455.964
2024-01-31State St US Extended Mkt Indx NL Cl C0.00860.0004310000
2023-12-31SSgA U.S. Extended Market Index Class I0.00860.0004310000
2023-12-31NT US Market Cap Idx Fd - L0.0030.0001109028635.5721
Total 2.96240.54061066475+35302+3.3%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cyteir Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.139-1.1390%6.537-117%1.016-212%1.016-212%
Book Value Per Share--4.0644.0640%5.203-22%1.786+127%1.786+127%
Current Ratio--28.07328.0730%25.706+9%18.270+54%18.270+54%
Debt To Asset Ratio--0.0450.0450%0.041+9%1.622-97%1.622-97%
Debt To Equity Ratio--0.0470.0470%0.043+10%0.023+109%0.023+109%
Dividend Per Share----0%-0%-0%-0%
Eps---1.280-1.2800%-1.170-9%-0.862-33%-0.862-33%
Free Cash Flow Per Share---1.190-1.1900%-1.034-13%-0.814-32%-0.814-32%
Free Cash Flow To Equity Per Share---1.183-1.1830%4.967-124%0.954-224%0.954-224%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---18.300--------
Intrinsic Value_10Y_min---15.387--------
Intrinsic Value_1Y_max---1.120--------
Intrinsic Value_1Y_min---1.089--------
Intrinsic Value_3Y_max---3.910--------
Intrinsic Value_3Y_min---3.683--------
Intrinsic Value_5Y_max---7.355--------
Intrinsic Value_5Y_min---6.709--------
Market Cap108714262.000+45%59396865.00059396865.0000%409298397.000-85%117173815.500-49%117173815.500-49%
Net Profit Margin----0%-0%-470.1250%-470.1250%
Operating Margin----0%-0%-503.2810%-503.2810%
Operating Ratio----0%-0%503.678-100%503.678-100%
Pb Ratio0.743+45%0.4060.4060%2.185-81%0.648-37%0.648-37%
Pe Ratio-2.360-83%-1.290-1.2900%-9.716+653%-2.751+113%-2.751+113%
Price Per Share3.020+45%1.6501.6500%11.370-85%3.255-49%3.255-49%
Price To Free Cash Flow Ratio-2.537-83%-1.386-1.3860%-10.996+693%-3.096+123%-3.096+123%
Price To Total Gains Ratio-2.651-83%-1.448-1.4480%1.739-183%0.145-1096%0.145-1096%
Quick Ratio--27.68027.6800%25.264+10%17.812+55%17.812+55%
Return On Assets---0.287-0.2870%-0.213-26%-0.624+118%-0.624+118%
Return On Equity---0.300-0.3000%-0.222-26%-0.131-56%-0.131-56%
Total Gains Per Share---1.139-1.1390%6.537-117%1.016-212%1.016-212%
Usd Book Value--146286000.000146286000.0000%187292000.000-22%64302750.000+127%64302750.000+127%
Usd Book Value Change Per Share---1.139-1.1390%6.537-117%1.016-212%1.016-212%
Usd Book Value Per Share--4.0644.0640%5.203-22%1.786+127%1.786+127%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.280-1.2800%-1.170-9%-0.862-33%-0.862-33%
Usd Free Cash Flow---42844000.000-42844000.0000%-37221000.000-13%-29286000.000-32%-29286000.000-32%
Usd Free Cash Flow Per Share---1.190-1.1900%-1.034-13%-0.814-32%-0.814-32%
Usd Free Cash Flow To Equity Per Share---1.183-1.1830%4.967-124%0.954-224%0.954-224%
Usd Market Cap108714262.000+45%59396865.00059396865.0000%409298397.000-85%117173815.500-49%117173815.500-49%
Usd Price Per Share3.020+45%1.6501.6500%11.370-85%3.255-49%3.255-49%
Usd Profit---43952000.000-43952000.0000%-41647000.000-5%-30366500.000-31%-30366500.000-31%
Usd Revenue----0%-0%2000.000-100%2000.000-100%
Usd Total Gains Per Share---1.139-1.1390%6.537-117%1.016-212%1.016-212%
 EOD+5 -3MRQTTM+0 -0YOY+4 -255Y+10 -2110Y+10 -21

4.2. Fundamental Score

Let's check the fundamental score of Cyteir Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.360
Price to Book Ratio (EOD)Between0-10.743
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than127.680
Current Ratio (MRQ)Greater than128.073
Debt to Asset Ratio (MRQ)Less than10.045
Debt to Equity Ratio (MRQ)Less than10.047
Return on Equity (MRQ)Greater than0.15-0.300
Return on Assets (MRQ)Greater than0.05-0.287
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Cyteir Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.381
Ma 20Greater thanMa 503.078
Ma 50Greater thanMa 1003.093
Ma 100Greater thanMa 2003.068
OpenGreater thanClose3.030
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets153,232
Total Liabilities6,946
Total Stockholder Equity146,286
 As reported
Total Liabilities 6,946
Total Stockholder Equity+ 146,286
Total Assets = 153,232

Assets

Total Assets153,232
Total Current Assets149,209
Long-term Assets4,023
Total Current Assets
Cash And Cash Equivalents 147,120
Other Current Assets 2,089
Total Current Assets  (as reported)149,209
Total Current Assets  (calculated)149,209
+/-0
Long-term Assets
Property Plant Equipment 1,699
Long-term Assets Other 2,324
Long-term Assets  (as reported)4,023
Long-term Assets  (calculated)4,023
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,315
Long-term Liabilities1,631
Total Stockholder Equity146,286
Total Current Liabilities
Short-term Debt 889
Accounts payable 1,128
Other Current Liabilities 3,298
Total Current Liabilities  (as reported)5,315
Total Current Liabilities  (calculated)5,315
+/-0
Long-term Liabilities
Long-term Liabilities Other 1,631
Long-term Liabilities  (as reported)1,631
Long-term Liabilities  (calculated)1,631
+/-0
Total Stockholder Equity
Common Stock35
Retained Earnings -138,114
Capital Surplus 284,365
Total Stockholder Equity (as reported)146,286
Total Stockholder Equity (calculated)146,286
+/-0
Other
Capital Stock35
Cash and Short Term Investments 147,120
Common Stock Shares Outstanding 35,273
Common Stock Total Equity35
Liabilities and Stockholders Equity 153,232
Net Debt -146,231
Net Invested Capital 146,286
Net Tangible Assets 146,286
Net Working Capital 143,894
Property Plant and Equipment Gross 3,521
Short Long Term Debt Total 889



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-31
> Total Assets 
31,369
13,735
195,388
153,232
153,232195,38813,73531,369
   > Total Current Assets 
30,437
12,131
193,077
149,209
149,209193,07712,13130,437
       Cash And Cash Equivalents 
29,012
10,938
189,723
147,120
147,120189,72310,93829,012
       Net Receivables 
164
63
38
0
03863164
       Inventory 
1,260
-63
-38
0
0-38-631,260
       Other Current Assets 
1
1,193
3,354
2,089
2,0893,3541,1931
   > Long-term Assets 
932
1,604
2,311
4,023
4,0232,3111,604932
       Property Plant Equipment 
788
1,287
2,055
1,699
1,6992,0551,287788
       Other Assets 
144
317
256
0
0256317144
> Total Liabilities 
59,705
61,766
8,096
6,946
6,9468,09661,76659,705
   > Total Current Liabilities 
1,972
3,137
7,511
5,315
5,3157,5113,1371,972
       Short-term Debt 
0
0
0
889
889000
       Accounts payable 
602
1,689
1,785
1,128
1,1281,7851,689602
       Other Current Liabilities 
1,370
1,448
5,726
3,298
3,2985,7261,4481,370
   > Long-term Liabilities 
57,733
58,629
585
1,631
1,63158558,62957,733
       Other Liabilities 
322
1,218
585
0
05851,218322
       Deferred Long Term Liability 
0
61
384
0
0384610
> Total Stockholder Equity
-28,336
-48,031
187,292
146,286
146,286187,292-48,031-28,336
   Common Stock
1
2
35
35
353521
   Retained Earnings -138,114-92,053-49,927-29,104
   Capital Surplus 
0
0
279,310
284,365
284,365279,31000
   Treasury Stock0000
   Other Stockholders Equity 
767
1,894
279,310
284,365
284,365279,3101,894767



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-38,253
Operating Income-38,253-38,253
 
Operating Expense (+$)
Research Development24,861
Selling General Administrative13,392
Selling And Marketing Expenses-
Operating Expense38,25338,253
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income-38,253
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-33,215-38,253
EBIT - interestExpense = 0
-33,215
-33,215
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--33,215
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-33,215
Tax Provision--
Net Income From Continuing Ops-33,215-33,215
Net Income-33,215
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Technical Analysis of Cyteir
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cyteir. The general trend of Cyteir is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cyteir's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cyteir Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.15 < 3.15 < 3.19.

The bearish price targets are: 2.99 > 2.97 > 2.96.

Tweet this
Cyteir Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cyteir Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cyteir Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cyteir Therapeutics Inc. The current macd is -0.01786096.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cyteir price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cyteir. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cyteir price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cyteir Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartCyteir Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cyteir Therapeutics Inc. The current adx is 20.10.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cyteir shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Cyteir Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cyteir Therapeutics Inc. The current sar is 2.9999.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cyteir Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cyteir Therapeutics Inc. The current rsi is 43.38. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Cyteir Therapeutics Inc Daily Relative Strength Index (RSI) ChartCyteir Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cyteir Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cyteir price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cyteir Therapeutics Inc Daily Stochastic Oscillator ChartCyteir Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cyteir Therapeutics Inc. The current cci is -110.46442368.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Cyteir Therapeutics Inc Daily Commodity Channel Index (CCI) ChartCyteir Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cyteir Therapeutics Inc. The current cmo is -15.07946718.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cyteir Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartCyteir Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cyteir Therapeutics Inc. The current willr is -81.25.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Cyteir Therapeutics Inc Daily Williams %R ChartCyteir Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cyteir Therapeutics Inc.

Cyteir Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cyteir Therapeutics Inc. The current atr is 0.06138048.

Cyteir Therapeutics Inc Daily Average True Range (ATR) ChartCyteir Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cyteir Therapeutics Inc. The current obv is 12,128,112.

Cyteir Therapeutics Inc Daily On-Balance Volume (OBV) ChartCyteir Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cyteir Therapeutics Inc. The current mfi is 19.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Cyteir Therapeutics Inc Daily Money Flow Index (MFI) ChartCyteir Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cyteir Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-12MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Cyteir Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cyteir Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.381
Ma 20Greater thanMa 503.078
Ma 50Greater thanMa 1003.093
Ma 100Greater thanMa 2003.068
OpenGreater thanClose3.030
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cyteir with someone you think should read this too:
  • Are you bullish or bearish on Cyteir? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cyteir? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cyteir Therapeutics Inc

I send you an email if I find something interesting about Cyteir Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cyteir Therapeutics Inc.

Receive notifications about Cyteir Therapeutics Inc in your mailbox!